A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?
Once again Europe’s premier oncology meeting provides the perfect venue for big pharmas including Pfizer, Roche and Astrazeneca to showcase important pivotal study…
A cooling of the M&A climate allows Asia-based groups to come to the fore.